Fig. 3

Receptor-associated protein (RAP) reduces mortality and neurological score but does not improve other functional parameters. Mortality rates (a) and neurological deficit assessment (b–f) 20 after 4 h middle cerebral artery occlusion following treatment with HEPES vehicle, rt-PA (10 mg/kg), RAP (2 mg/kg) or their combination. RAP reduced mortality with or without rt-PA (a) and improved neurological score when co-administered with rt-PA (b). In other functional tests, such as hanging wire (c) and ANY-Maze recording over 5 min of total distance travelled (d), total time immobile (e) and the number of immobile episodes (f), RAP treatment did not offer any functional benefit. Data is shown as individual animals with median + IQR (b) or mean ± SEM (c–f). In a black and white annotations above each column stipulate fatalities out of total animal number and percentage of death in each group, respectively. In b, c n = 11 for vehicle, 10 for rt-PA, 8 for rt-PA + RAP and 7 for RAP. In d–f n = 6 for vehicle, 9 for rt-PA, 8 for rt-PA + RAP and 7 for RAP. In a *P < 0.05 by Log-rank (Mantel-Cox) test; in b *P < 0.05 by Kruskal–Wallis ANOVA with Dunn’s multiple comparisons test of selected groups; in c–f ordinary one-way ANOVA with Sidak’s post hoc of selected groups unless t-test is specified. Outliers are denoted in black symbols and excluded from the analysis